|
|
Article: Synaptic Licenses Preclinical Receptor Compounds To P&G.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Synaptic Pharmaceutical Corp. said it granted Procter & Gamble Pharmaceuticals Inc. an exclusive patent license for two of its alpha-2 adrenergic receptor compounds.
The agreement also allows Cincinnati-based Procter & Gamble to operate under Synaptic's patents for all therapeutic indications for the two compounds.
Kathleen Mullinix, president and CEO of Paramus, N.J.-based Synaptic, told BioWorld Today that she couldn't discuss specific indications P&G is planning to study. The research is in the preclinical stage. She did say P&G will pay an up-front licensing fee plus milestones and royalties if a product is commercialized. ...